Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
about
Next-generation surveillance strategies for patients with lymphomaCD19 antigen in leukemia and lymphoma diagnosis and immunotherapyHCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation.Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.Prognostic significance of micrometastatic bone marrow involvement.Detection and clinical importance of micrometastatic disease.Micrometastatic bone marrow involvement: detection and prognostic significance.Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC).Minimal Residual Cancer Detection in Hematopoietic Stem Cell Products and Its Prognostic Significance in Patients With Breast Cancer, Lymphoma, or Multiple Myeloma.Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.Inroads in the therapy of indolent lymphomas: exploiting biological insights.Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.Monoclonal antibodies and autologous stem cell transplantation for lymphoma.Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.Minimal residual disease in gastrointestinal cancer.Adenovirus infection of primary malignant lymphoid cells.Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.The use of radioimmunoconjugates in stem cell transplantation.Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies.Harvesting, processing and inventory management of peripheral blood stem cellsThe polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers.Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?Stem cell transplantation in follicular lymphoma: progress at last?Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beadsPeripheral blood involvement in non-Hodgkin's lymphoma detected by clonal gene rearrangement as a biological prognostic marker.High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasImmune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell productsHigh tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR.Sequential detection of alphafetoprotein-bearing cells in blood stem cell fraction of germ cell tumour patients.The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretic field-flow-fractionation.Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?Rituximab in hematopoietic cell transplantation.Autologous transplant of follicular lymphoma in the era of rituximab.Biology and treatment of follicular lymphoma.Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
P2860
Q28084956-2835CDAD-A492-4F3D-A3CE-F837D85AF221Q28270773-82A1B693-8F80-4709-B8A1-1AD4CDF482DCQ33225377-EFA22A55-3AE9-46EF-BF4E-1DE392021224Q33335301-15AF2237-0867-4114-8901-0DB0D749A153Q33341595-789FC3D2-ECD0-490A-A7E5-AB6E170722C0Q33538449-EF397307-C75D-48DC-864E-21A51DDC07FCQ33678970-B9D88F9F-431C-4597-B76A-37326ACBAF69Q33752919-82EF12CD-8414-497B-B1E6-0D519FFA0AD8Q33762537-41776B94-F1DE-4645-8B3E-AA796A6B5C45Q33873523-C2559585-31EA-4E48-ACF0-24AF22EC7BEBQ33878418-8979A043-54A3-4A4D-B68D-ACF6D4D853B9Q33889264-9E884E6D-3ACF-458B-9F0E-3DFB5164E288Q33956237-219EC7CC-A234-43E4-8D3F-9BFAAD2A1E16Q34040863-11941C8B-9B34-428F-879F-069257EA9A81Q34102941-22E7C346-7780-447C-B078-81DFF35BD9B2Q34229700-5F584555-48E9-49AF-B7F0-D755D2ECCF6EQ34306214-AEB79F82-2020-4754-AE89-9A570541E80AQ34465191-898CE82F-60D8-4A35-8EBB-92FECFBC6B53Q34573981-76B9EEF3-D284-4B78-AA5A-8664747BF7B2Q34636090-DD1019A0-7CC7-49C7-A9EB-AF8A6434E5B9Q34679582-4245B802-8B86-466A-B830-D21B44313840Q35169842-03F72AC6-2050-4DBA-894C-9AC82CD7F291Q35199782-2120048D-BBEC-493B-84DC-F8EB442200FFQ35367235-AF64FF06-11CA-4B02-86F2-5C7EDEA804EBQ35819325-4241157E-2F55-468F-A793-C75DC9CECD86Q35920882-20D5602B-F709-4D92-956F-8B5D45CC8771Q35977101-F05557C3-78E7-4F0A-B163-8423AF038B4BQ35977640-83520F1E-1030-4730-B4C0-9968238AF153Q36077893-5B413DB9-CC12-4F13-8E6D-E402E1810773Q36082845-807FFB06-AB55-4883-896C-F2FF650C3B12Q36623226-15C4E109-DC6E-4B9A-B12E-CA1F70447681Q36643613-3DE1C59D-EE23-470C-AFAC-CE382DA1DD56Q37303777-5C46E0F9-B2DD-4BB0-8B0E-7A2F693F4883Q37577874-2E9D7CCE-C4AC-4815-83DB-048F80A4AE8AQ37737311-5E66285A-A1D6-4FCC-8A40-C60A9FDF19DDQ37742624-3EF54704-9A32-44D0-A97E-319104BC818BQ37810118-36CD60AF-179C-4EAA-83B9-852603F7EF97Q37824996-1472390E-A7EB-4E35-9549-D48AA7C02BACQ38001363-2BE714FA-7301-4354-B17E-A023928DFCC2Q38017138-FF763F6D-FFC9-4E1A-B70B-6A08F04AA2CB
P2860
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Immunologic purging of marrow ...... lantation for B-cell lymphoma.
@en
type
label
Immunologic purging of marrow ...... lantation for B-cell lymphoma.
@en
prefLabel
Immunologic purging of marrow ...... lantation for B-cell lymphoma.
@en
P2093
P1476
Immunologic purging of marrow ...... lantation for B-cell lymphoma.
@en
P2093
Freedman AS
Freeman GJ
Gribben JG
Rabinowe SN
P304
P356
10.1056/NEJM199111283252201
P407
P577
1991-11-01T00:00:00Z